Usefulness of Atherogenic Dyslipidemia for Predicting Cardiovascular Risk in Patients With Angiographically Defined Coronary Artery Disease

American Journal of Cardiology

Volumn 100, Issue 10, 2007, Pages 1511-1516

  Arca, Marcello ^a   Montali, Anna ^a   Valiante, Sofia ^a   Campagna, Filomena ^a   Pigna, Giovanni ^a   Paoletti, Vincenzo ^a   Antonini, Roberto ^a   Barillà, Francesco ^b   Tanzilli, Gaetano ^b   Vestri, Annarita ^b   Gaudio, Carlo ^b  

^a I Medical School   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ANGINA PECTORIS; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG UTILIZATION; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; RISK ASSESSMENT; STROKE; SURVIVAL ANALYSIS; TRIGLYCERIDES;

EID: 35748982933     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.049     Document Type: Article

References (21)

1. Grundy S.M. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am J Cardiol 75 suppl (1995) 45B-52B
2. Twickler T.B., Dallinga-Thie G.M., Cohn J.S., and Chapman M.J. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 109 (2004) 1918-1925
3. Packard C.J., and Saito Y. Non-HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb 11 (2004) 6-14
4. Grundy S.M. A constellation of complications: the metabolic syndrome. Clin Cornerstone 7 (2005) 36-45
5. Wyszynski D.F., Dawn M., Waterworth D.M., Philip J., Barter P.J., Cohen J., Kesäniemi Y.A., Mahley R.W., McPherson R., Waeber G., et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 95 (2005) 194-198
6. Vinik A.I. The metabolic basis of atherogenic dyslipidemia. Clin Cornerstone 7 (2005) 27-35
7. Austen W.G., Edwards J.E., Frye R.L., Gensini G.G., Gott V.L., Griffith L.S., McGoon D.C., Murphy M.L., and Roe B.B. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 51 suppl (1975) 5-40
8. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1059
9. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1 suppl (2000) S4-S19
10. Friedewald W.T., Levy R.J., and Fredrickson D.S. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
11. Lipid and lipoprotein analysis. Manual of Laboratory Operations (1984), Lipid Research Clinics Program, Washington, District of Columbia Publication NIH F5-628
12. Campagna F., Montali A., Baroni M.G., Antonini T.M., Ricci G., Antonini R., Verna R., and Arca M. Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the β3-adrenergic receptor and the intestinal fatty acid binding protein-2 gene influence the lipid phenotypic expression in familial combined hyperlipidemia. Metabolism 51 (2002) 1298-1305
13. Montali A., Vega G.L., and Grundy S.M. Concentration of apolipoprotein AI-containing particles in patients with hypoalphalipoproteinemia. Arterioscler Thromb 14 (1994) 511-517
14. Arca M., Vega G.L., and Grundy S.M. Hypercholesterolemia in postmenopausal women: metabolic defects and response to low-dose lovastatin. JAMA 271 (1994) 453-459
15. Matthews D.R., Hasker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
17. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., McNamara J.R., Kashyap M.L., Hershman J.M., Wexler L.F., and Rubins H.B. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
18. Miller M., Seidler A., Moalemi A., and Pearson T.A. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 31 (1998) 1252-1257
19. Bittner V., Hardison R., Kelsey F.S., Weiner B.H., Jacobs A.K., and Sopko G. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 106 (2002) 2537-2542
20. Stein E.A., Lane M., and Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 81 suppl (1998) 66B-69B
21. Vanuzzo D., Pilotto L., Ambrosio G.B., Pyorala K., Lehto S., De Bacquer D., De Backer G., Wood D., and EUROASPIRE Study Group. Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE [European Action on Secondary Prevention Through Intervention to Reduce Events] study. Atherosclerosis 153 (2000) 505-517